Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Long-Term Survival In Patients With Acute Steroid Refractory Graft-Versus-Host-Disease (SR-GVHD) Treated With Infliximab Combined With Daclizumab

Sanaz Nicky Soltani, MD, Ramaprasad Srinivasan, MD, PhD, Theresa Jerussi, PAc, A. John Barrett, Thomas E Hughes, PharmD, BCOP, Catalina Ramos, RN, BSN, Lisa Cook, RN, BSN, Elena Cho, RN, MSN, Richard W. Childs, MD

Blood (2013) 122 (21): 4624.

https://doi.org/10.1182/blood.V122.21.4624.4624

Published: 2013

Journal Articles

Loss of Function of the VHL Tumor Suppressor Gene Resurrects An Endogenous Retrovirus in Kidney Cancer That Encodes a Tumor Antigen Targeted by Allogeneic T-Cells Following Hematopoietic Cell Transplantation (HCT).

Elena Cherkasova, Elizabeth Malinzak, Sheila Rao, Vera N. Senchenko, Anna V. Kudryavtseva, Lev L. Kiselev, Yoshiyuki Takahashi, MD, PhD, Nanae Harashima, W. Marston Linehan, M.D, Ramaprasad Srinivasan, MD, PhD, Michael I. Lerman, Richard W. Childs, MD

Blood (2009) 114 (22): 467.

https://doi.org/10.1182/blood.V114.22.467.467

Published: 2009

Journal Articles

Impact of KIR and HLA Genotypes on Outcome in Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Using HLA Matched Related Donors.

Ramaprasad Srinivasan, MD, PhD, Mary Carrington, Ph.D., Dante Suffredini, M.S., Aleah Smith, Maureen Martin, Ph.D, Maria Berg, M.S., A. John Barrett, M.D., Shivani Srivastava, M.D, Andreas Lundqvist, Ph.D., Hisayuki Yokoyoma, M.D., Bipin N. Savani, M.D., Richard W. Childs, M.D.

Blood (2006) 108 (11): 323.

https://doi.org/10.1182/blood.V108.11.323.323

Published: 2006

Journal Articles

High Response Rates in Acute Steroid Refractory Graft-Versus-Host Disease (GVHD) Following Combined Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-2 (IL-2) Blockade.

Ramaprasad Srinivasan, MD, PhD, Nancy Geller, PhD, Colleen Dorrance, MD, Igor Espinoza-Delgado, MD, A. John Barrett, MD, Yoshiyuki Takahashi, MD, PhD, Richard W. Childs, MD

Blood (2005) 106 (11): 1801.

https://doi.org/10.1182/blood.V106.11.1801.1801

Published: 2005

Journal Articles

Adoptive Infusion of Allogeneic KIR Ligand Mismatched NK Cells Reduce GVHD in an MHC Matched Allogeneic Stem Cell Transplantation Model.

Andreas Lundqvist, PhD, Leigh Samsel, Michael Eckhaus, Ramaprasad Srinivasan, MD, PhD, Yoshiyuki Takahashi, MD, PhD, Maarten Snoeijs, MD, Philip J. McCoy, Jr., PhD, Maria Berg, Richard Childs, MD

Blood (2005) 106 (11): 1310.

https://doi.org/10.1182/blood.V106.11.1310.1310

Published: 2005

Journal Articles

Pulmonary Function Abnormalities 5 Years or More Following Myeloablative and Non-Myeloablative Allogeneic Stem Cell Transplantation for Hematological Disorders - Impact of Chronic GVHD.

Bipin N. Savani, MD, Ramaprasad Srinivasan, MD, PhD, Aldemar Montero, MD, Anurag Singh, MD, Aarthi Shenoy, MD, Shervin Kamipour, MD, Richard Childs, MD, A. John Barrett, MD

Blood (2005) 106 (11): 1116.

https://doi.org/10.1182/blood.V106.11.1116.1116

Published: 2005

Journal Articles

Evaluation of Three Different Cyclosporine-Based Graft Versus Host Disease (GVHD) Prophylaxis Regimens Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST).

Ramaprasad Srinivasan, MD, PhD, Nancy Geller, PhD, Sakti Chakrabarti, MD, Igor Espinoza-Delgado, MD, Teresa Donohue, Susan Leitman, MD, Charles D. Bolan, MD, Elizabeth J. Read, MD, John A. Barrett, MD, Richard W. Childs, MD

Blood (2004) 104 (11): 1236.

https://doi.org/10.1182/blood.V104.11.1236.1236

Published: 2004

Journal Articles

Potent Graft-Versus-Renal Cell Carcinoma (RCC) Effects in a Murine Minor Histocompatibility Antigen (mHa)-Mismatched Allogeneic Transplant Model.

Andreas Lundqvist, PhD, Ramaprasad Srinivasan, MD, PhD, Dante Suffredini, BS, Yoshiyuki Takahashi, MD, PhD, Jason Wynberg, MD, Takehito Igarashi, MD, PhD, Amy Reese, MD, Warren Shlomchik, MD, Richard Childs, MD

Blood (2004) 104 (11): 4982.

https://doi.org/10.1182/blood.V104.11.4982.4982

Published: 2004

Journal Articles

Cd8+ T-Cells Specifically Cytotoxic to Renal Cell Carcinoma (RCC) Cells Can Be Isolated from Patients with Regressing Metastatic Kidney Cancer after Allogeneic Nonmyeloablative Hematopoietic Cell Transplantation (NMHCT).

Yoshiyuki Takahashi, MD, PhD, Othon Mena, MD, Ramaprasad Srinivasan, MD, PhD, Takehito Igarashi, MD, PhD, Andreas Lundqvist, PhD, Dante Suffredini, J. Philip McCoy, Jr, PhD, Ken-ichi Hanada, MD, PhD, Marston Linehan, MD, Richard Childs, MD

Blood (2004) 104 (11): 4984.

https://doi.org/10.1182/blood.V104.11.4984.4984

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Long-Term Survival In Patients With Acute Steroid Refractory Graft-Versus-Host-Disease (SR-GVHD) Treated With Infliximab Combined With Daclizumab

Loss of Function of the VHL Tumor Suppressor Gene Resurrects An Endogenous Retrovirus in Kidney Cancer That Encodes a Tumor Antigen Targeted by Allogeneic T-Cells Following Hematopoietic Cell Transplantation (HCT).

Impact of KIR and HLA Genotypes on Outcome in Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Using HLA Matched Related Donors.

High Response Rates in Acute Steroid Refractory Graft-Versus-Host Disease (GVHD) Following Combined Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-2 (IL-2) Blockade.

Adoptive Infusion of Allogeneic KIR Ligand Mismatched NK Cells Reduce GVHD in an MHC Matched Allogeneic Stem Cell Transplantation Model.

Pulmonary Function Abnormalities 5 Years or More Following Myeloablative and Non-Myeloablative Allogeneic Stem Cell Transplantation for Hematological Disorders - Impact of Chronic GVHD.

Evaluation of Three Different Cyclosporine-Based Graft Versus Host Disease (GVHD) Prophylaxis Regimens Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST).

Potent Graft-Versus-Renal Cell Carcinoma (RCC) Effects in a Murine Minor Histocompatibility Antigen (mHa)-Mismatched Allogeneic Transplant Model.

Cd8+ T-Cells Specifically Cytotoxic to Renal Cell Carcinoma (RCC) Cells Can Be Isolated from Patients with Regressing Metastatic Kidney Cancer after Allogeneic Nonmyeloablative Hematopoietic Cell Transplantation (NMHCT).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only